244 related articles for article (PubMed ID: 36768557)
1. Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment.
Pandey P; Khan F; Upadhyay TK; Sharangi AB
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768557
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
3. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
4. Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
[TBL] [Abstract][Full Text] [Related]
5. Cigarette tar phenols impede T cell cycle progression by inhibiting cyclin-dependent kinases.
Frazer-Abel AA; McCue JM; Lazis S; Portas M; Lambert C; Freed BM
Mol Immunol; 2007 Jan; 44(4):488-93. PubMed ID: 16584776
[TBL] [Abstract][Full Text] [Related]
6. Cell-Cycle Therapeutics Come of Age.
Ingham M; Schwartz GK
J Clin Oncol; 2017 Sep; 35(25):2949-2959. PubMed ID: 28580868
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event.
Zancai P; Cariati R; Rizzo S; Boiocchi M; Dolcetti R
Oncogene; 1998 Oct; 17(14):1827-36. PubMed ID: 9778049
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of cyclin-dependent kinase activity and G1- to S-phase transition in human lymphocytes by the human T-cell leukemia/lymphotropic virus type 1 Tax protein.
Schmitt I; Rosin O; Rohwer P; Gossen M; Grassmann R
J Virol; 1998 Jan; 72(1):633-40. PubMed ID: 9420268
[TBL] [Abstract][Full Text] [Related]
10. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4.
Chan FK; Zhang J; Cheng L; Shapiro DN; Winoto A
Mol Cell Biol; 1995 May; 15(5):2682-8. PubMed ID: 7739548
[TBL] [Abstract][Full Text] [Related]
11. Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells.
Shimizu T; Awai N; Takeda K
Oncogene; 2000 Sep; 19(40):4640-6. PubMed ID: 11030153
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
13. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
[TBL] [Abstract][Full Text] [Related]
14. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
[TBL] [Abstract][Full Text] [Related]
15. Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition.
Chaikovsky AC; Sage J
Mol Cancer Res; 2018 Oct; 16(10):1454-1457. PubMed ID: 29934327
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids induce G1 as well as S-phase lengthening in normal human stimulated lymphocytes: differential effects on cell cycle regulatory proteins.
Baghdassarian N; Catallo R; Mahly MA; Ffrench P; Chizat F; Bryon PA; Ffrench M
Exp Cell Res; 1998 May; 240(2):263-73. PubMed ID: 9596999
[TBL] [Abstract][Full Text] [Related]
17. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
18. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
19. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
20. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
